Clinical Trials

Inclusion Criteria:

• Eczema patients referred for patch testing to at least the Mayo Standard and Extended Standard Series who demonstrate 1+ or higher positivity to one or more of the Mayo 40 fragrance allergens will be offered participation (standard Mayo methodology; https://pubmed.ncbi.nlm.nih.gov/30422883/).Approximately 25% of the study population will be 
• patients who demonstrate a 1+. The rest of the population will be those who demonstrate a positivity of 2+ or higher. Eligible patients may enroll as soon as study Inclusion/Exclusion criteria are met. For example, for those patients who have staggered patch test series start dates, as soon as the first series final reading on day 5 is completed demonstrating fragrance allergy, enrollment will be offered, even if they have not completed their other patch tests series. Note that patch testing to patient products concurrently with standardized patch test series is common clinical practice.

Exclusion Criteria:

• Patients younger than 18 years.
• Patients who are only positive to Hydroperoxides or Linalool or Hydroperoxides of Limonene alone. Patients allergic to both are not excluded from the study.
• Patients on systemic immunosuppressants or who have used topical immunosuppressants on the patch testing location (e.g., the back) in the last 2 weeks.
• Patients who are pregnant.
• Patients not willing to sign informed consent form.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 11/1/23. Questions regarding updates should be directed to the study team contact.